# Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

> **NCT00103298** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Colorectal Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** FOLFOX regimen
- **DRUG:** fluorouracil
- **DRUG:** isolated perfusion
- **DRUG:** leucovorin calcium
- **DRUG:** melphalan
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00103298
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103298, "Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00103298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*